Table 3.
Cost of antiretroviral drugs available in France in 2013*
| Antiretroviral drug (Branded formulation – manufacturers) | Usual daily dosing (Adult) | Monthly cost (€) |
|---|---|---|
| Nucleoside reverse transcriptase inhibitors | ||
| Abacavir (Ziagen® – ViiV Healthcare) | 300 mg×2 or 600 mg×1 | 286 |
| Emtricitabine (Emtriva® – Gilead Sciences) | 200 mg×1 | 163 |
| Didanosine (Videx® – Bristol Myers Squibb) | ≥60 kg: 400 mg×1 | 218 |
| <60 kg: 250 mg×1 | 135 | |
| Lamivudine (Epivir® – ViiV Healthcare) | 150 mg×2 | 181 |
| Zidovudine (Retrovir® – ViiV Healthcare) | 300 mg×2 | 238 |
| Nucleotide reverse transcriptase inhibitors | ||
| Tenofovir (Viread® – Gilead Sciences) | 245 mg×1 | 366 |
| Non-nucleoside reverse transcriptase inhibitors | ||
| Efavirenz (Sustiva® – Bristol Myers Squibb) | 600 mg×1 | 315 |
| Etravirine (Intelence® – Janssen) | 200 mg×2 | 505 |
| Nevirapine (Viramune® – Boehringer Ingelheim) | 200 mg×1 for 14 days | 56 (14 days) |
| then 200 mg×2 | 226 | |
| or 400 mg LR×1/j | 280 | |
| Rilpivirine (Edurant® – Janssen) | 25 mg×1 | 270 |
| Protease inhibitors | ||
| Atazanavir/ritonavir (Reyataz®/Norvir®) – (Bristol Myers Squibb/Abbott) | 300/100 mg×1 or | 455/27 |
| 400 mg×1 (non-ritonavir-boosted) | 455 | |
| Darunavir/ritonavir(Prezista®/Norvir®)– (Janssen/Abbott) | ARV naive: 800 mg/100×1 | 490/27 |
| ARV experienced: 600 mg/100×2 | 735/54 | |
| Fosamprenavir/ritonavir (Telzir®/Norvir®) – (ViiV Healthcare/Abbott) | 700/100 mg×2 | 377/54 |
| Lopinavir/ritonavir (Kaletra® – Abbott) | 400/100 mg×2 | 476 |
| Saquinavir/ritonavir (Invirase®/Norvir®) – (Roche/Abbott) | 1000/100 mg×2 | 399/54 |
| Tipranavir/ritonavir (Aptivus®/Norvir®) – (Boehringer–Ingelheim/Abbott) | 500/200 mg×2 | 810/108 |
| Integrase inhibitor | ||
| Raltegravir (Isentress® – Merck) | 400 mg×2 | 700 |
| CCR5-antagonist | ||
| Maraviroc (Celsentri® – ViiV Healthcare) | 50 to 600 mg×2 | 729 to 1684 |
| Fusion inhibitor | ||
| Enfuvirtide (Fuzeon® – Roche) | 90 mg×2 (subcutaneous injections) | 1684 |
| Fixed-dose co-formulations | ||
| Abacavir+lamivudine (Kivexa® – ViiV Healthcare) | 600 mg+300 mg | 412 |
| Tenofovir+emtricitabine (Truvada® – Gilead Sciences) | 245 mg+200 mg | 520 |
| Tenofovir+emtricitabine+efavirenz (Atripla® – Bristol Myers Squibb) | 245 mg+200 mg+600 mg | 746 |
| Tenofovir+emtricitabine+rilpivirine (Eviplera® – Gilead Sciences) | 245 mg+200 mg+25 mg | 756 |
*
http://medicprix.sante.gouv.fr/medicprix/rechercheSpecialite.do?parameter=rechercheSpecialite (Accessed Aug 6, 2013).